Summary of observational clinical study PONDEROSA
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A90249%2F25%3A00143433" target="_blank" >RIV/00216224:90249/25:00143433 - isvavai.cz</a>
Result on the web
<a href="https://www.uniklinikum-jena.de/kim2/H%C3%A4matologie+und+Internistische+Onkologie/Forschung/Studienzentrale/Eigeninitiierte+Studien/Ponderosa.html" target="_blank" >https://www.uniklinikum-jena.de/kim2/H%C3%A4matologie+und+Internistische+Onkologie/Forschung/Studienzentrale/Eigeninitiierte+Studien/Ponderosa.html</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Summary of observational clinical study PONDEROSA
Original language description
This study aimed at giving a picture of real‐life treatment with ponatinib in CML patients. The study assessed the incidence of adverse events (AEs) and response to the treatment in the clinical practice.
Czech name
—
Czech description
—
Classification
Type
V<sub>souhrn</sub> - Summary research report
CEP classification
—
OECD FORD branch
30230 - Other clinical medicine subjects
Result continuities
Project
—
Continuities
—
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Number of pages
12
Place of publication
Jena, Germany
Publisher/client name
University Hospital Jena
Version
—